Published in Infect Immun on October 01, 1998
Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater (2010) 1.45
Subunit vaccine against the seven serotypes of botulism. Infect Immun (2007) 1.39
Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun (2007) 1.37
Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun (2001) 1.20
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines (2008) 1.13
Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun (2005) 1.10
Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine (2007) 1.04
Pichia pastoris fermentation with mixed-feeds of glycerol and methanol: growth kinetics and production improvement. J Ind Microbiol Biotechnol (2003) 1.03
Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting. Protein Eng Des Sel (2010) 0.94
Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens. Hum Vaccin Immunother (2012) 0.90
Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris. Microb Cell Fact (2005) 0.89
Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes. Infect Immun (2009) 0.89
Quantum dot immunoassays in renewable surface column and 96-well plate formats for the fluorescence detection of botulinum neurotoxin using high-affinity antibodies. Biosens Bioelectron (2009) 0.87
Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells. Infect Immun (2011) 0.87
Botulinum toxin: bioweapon & magic drug. Indian J Med Res (2010) 0.86
Subunit vaccine efficacy against Botulinum neurotoxin subtypes. Vaccine (2011) 0.81
Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication. Int Immunol (2011) 0.80
Characterization of new formalin-detoxified botulinum neurotoxin toxoids. Clin Vaccine Immunol (2008) 0.80
New equine antitoxins to botulinum neurotoxins serotypes A and B. Biologicals (2012) 0.80
Synergistic capture of Clostridium botulinum type A neurotoxin by scFv antibodies to novel epitopes. Biotechnol Bioeng (2011) 0.79
Oral vaccination with an adenovirus-vectored vaccine protects against botulism. Vaccine (2013) 0.78
The receptor binding domain of botulinum neurotoxin serotype A (BoNT/A) inhibits BoNT/A and BoNT/E intoxications in vivo. Clin Vaccine Immunol (2013) 0.78
Characterization and immunological activity of different forms of recombinant secreted Hc of botulinum neurotoxin serotype B products expressed in yeast. Sci Rep (2015) 0.77
Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol (2008) 0.76
Adenovirus F protein as a delivery vehicle for botulinum B. BMC Immunol (2010) 0.76
Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system. Hum Vaccin Immunother (2015) 0.75
Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles. Hum Vaccin Immunother (2016) 0.75
Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism. Toxins (Basel) (2017) 0.75
Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature (1992) 8.39
Foreign gene expression in yeast: a review. Yeast (1992) 3.20
Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem (1993) 2.79
A common subunit structure in Clostridium botulinum type A, B and E toxins. Biochem Biophys Res Commun (1972) 2.78
Recent advances in the expression of foreign genes in Pichia pastoris. Biotechnology (N Y) (1993) 2.77
Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol (1986) 2.66
Pichia pastoris as a host system for transformations. Mol Cell Biol (1985) 2.60
PREPARATION AND ASSAY OF THE INTERNATIONAL STANDARDS FOR CLOSTRIDIUM BOTULINUM TYPES A, B, C, D AND E ANTITOXINS. Bull World Health Organ (1963) 2.30
Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect Immun (1987) 1.97
Clostridial neurotoxins: handling and action at the cellular and molecular level. Curr Top Microbiol Immunol (1986) 1.84
Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol (1986) 1.83
High-level expression of tetanus toxin fragment C in Pichia pastoris strains containing multiple tandem integrations of the gene. Biotechnology (N Y) (1991) 1.78
Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun (1995) 1.61
Structure and function of Clostridium botulinum toxins. Microbiol Immunol (1995) 1.60
Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem (1994) 1.57
Analysis of the immune response to papain digestion products of tetanus toxin. Acta Pathol Microbiol Immunol Scand C (1984) 1.41
Inactivation of Clostridium botulinum type A neurotoxin by trypsin and purification of two tryptic fragments. Proteolytic action near the COOH-terminus of the heavy subunit destroys toxin-binding activity. Eur J Biochem (1985) 1.41
Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J (1992) 1.39
Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol (1988) 1.32
STUDIES ON IMMUNITY TO TOXINS OF CLOSTRIDIUM BOTULINUM. IX. IMMUNOLOGIC RESPONSE OF MAN TO PURIFIED PENTAVALENT ABCDE BOTULINUM TOXIOD. J Immunol (1963) 1.32
Rapid selection using G418 of high copy number transformants of Pichia pastoris for high-level foreign gene expression. Biotechnology (N Y) (1994) 1.22
Proteolytic cleavage of synthetic fragments of vesicle-associated membrane protein, isoform-2 by botulinum type B neurotoxin. Eur J Biochem (1993) 1.22
A 50-kDa fragment from the NH2-terminus of the heavy subunit of Clostridium botulinum type A neurotoxin forms channels in lipid vesicles. Eur J Biochem (1987) 1.12
Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen. Toxicon (1995) 1.09
High level expression of heterologous proteins in methylotrophic yeast Pichia pastoris. J Basic Microbiol (1988) 0.97
Studies on immunity to toxins of Clostridium botulinum. VIII. Immunological response of man to purified bivalent AB botulinum toxoid. J Immunol (1962) 0.91
Heterologous combinations of heavy and light chains from botulinum neurotoxin A and tetanus toxin inhibit neurotransmitter release in Aplysia. J Biol Chem (1991) 0.85
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Uncertainty in predictions of the climate response to rising levels of greenhouse gases. Nature (2005) 7.46
Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Use of brief cognitive tests to identify individuals in the community with clinically diagnosed Alzheimer's disease. Int J Neurosci (1991) 4.53
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol (2000) 4.01
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Inhibition by acetylene of conventional hydrogenase in nitrogen-fixing bacteria. Nature (1976) 3.11
Telling the truth about terminal cancer. JAMA (1998) 3.07
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun (2005) 3.06
Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol (1989) 2.49
Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol (1997) 2.47
Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation (2001) 2.46
Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46
Family preservation using multisystemic therapy: an effective alternative to incarcerating serious juvenile offenders. J Consult Clin Psychol (1992) 2.43
Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol (1992) 2.42
Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol (1993) 2.39
A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1988) 2.38
Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30
Vacuum pack technique of temporary abdominal closure: a 7-year experience with 112 patients. J Trauma (2000) 2.13
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08
A case-control study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1987) 2.07
Intracisternal A-particle genes in Mus musculus: a conserved family of retrovirus-like elements. Mol Cell Biol (1981) 2.07
Encephalopathy and fatty degeneratiof on the viscera in northeastern Thailand. Clinical syndrome and epidemiology. Pediatrics (1971) 2.00
The role of autolysins during vegetative growth of Bacillus subtilis 168. Microbiology (1998) 1.97
Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol (1989) 1.92
Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J Mol Biol (2006) 1.92
Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res (2000) 1.86
Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel (2010) 1.80
Reversible hypothyroidism in Addison's disease. Lancet (1972) 1.78
Impact of interruptions and distractions on dispensing errors in an ambulatory care pharmacy. Am J Health Syst Pharm (1999) 1.77
Physical and biological properties of dengue-2 virus and associated antigens. J Virol (1970) 1.75
Development of vaccines for prevention of botulism. Biochimie (2000) 1.73
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2000) 1.71
Measuring standards of care for early breast cancer in an insured population. J Clin Oncol (1997) 1.71
Oral aspirin in postoperative pain: a quantitative systematic review. Pain (1999) 1.71
Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol (2011) 1.70
Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med (1991) 1.67
Systematic review of the use of honey as a wound dressing. BMC Complement Altern Med (2001) 1.63
Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol (2005) 1.62
Pulmonary function in firefighters: acute changes in ventilatory capacity and their correlates. Br J Ind Med (1979) 1.61
Changes in lung function following the surgical treatment of bullous emphysema. Q J Med (1970) 1.61
Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease. Am J Physiol Regul Integr Comp Physiol (2000) 1.60
The efficacy of specimen radiography in evaluating the surgical margins of impalpable breast carcinoma. AJR Am J Roentgenol (1994) 1.54
Seeking a simple measure of analgesia for mega-trials: is a single global assessment good enough? Pain (2001) 1.51
Safety, accuracy, and diagnostic yield of needle localization biopsy of the breast performed using local anesthesia. J Am Coll Surg (1994) 1.49
Confidence, uncertainty and decision-support relevance in climate predictions. Philos Trans A Math Phys Eng Sci (2007) 1.49
Modeling particle exposure in U.S. trucking terminals. Environ Sci Technol (2006) 1.49
Dose coefficients for the embryo and foetus following intakes of radionuclides by the mother. J Radiol Prot (2002) 1.47
The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol (1992) 1.45
2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol (2000) 1.43
Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab (2001) 1.42
Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia (2006) 1.42
Deletions of fetal and adult muscle cDNA in Duchenne and Becker muscular dystrophy patients. EMBO J (1987) 1.40
The use of viscoelastic substances in the drainage of postoperative suprachoroidal hemorrhage. Ophthalmic Surg (1989) 1.40
Fungal virus capsids, cytoplasmic compartments for the replication of double-stranded RNA, formed as icosahedral shells of asymmetric Gag dimers. J Mol Biol (1994) 1.39
Health effects of gasoline exposure. II. Mortality patterns of distribution workers in the United States. Environ Health Perspect (1993) 1.39
Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol (1999) 1.39
Pulmonary effects of exposures in silicon carbide manufacturing. Br J Ind Med (1984) 1.39
Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: a case for aggressive therapy to the tumor bearing quadrant. Int J Radiat Oncol Biol Phys (1993) 1.38
Corneal traction suture in trabeculectomy. Ophthalmic Surg (1991) 1.37
Estimation of the diesel exhaust exposures of railroad workers: I. Current exposures. Am J Ind Med (1988) 1.35
Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg (1995) 1.35
Human lung tryptase. Purification and characterization. J Biol Chem (1984) 1.33
Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol (1998) 1.32
Modeling Pichia pastoris growth on methanol and optimizing the production of a recombinant protein, the heavy-chain fragment C of botulinum neurotoxin, serotype A. Biotechnol Bioeng (2000) 1.31
Low-temperature-induced changes in intracellular fatty acid fluxes in Dunaliella salina. Arch Biochem Biophys (1985) 1.30
Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc (1984) 1.30
Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice. Proc Natl Acad Sci U S A (1993) 1.28
Risk of death from Alzheimer's disease in a community population of older persons. Am J Epidemiol (1991) 1.28
Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat (1996) 1.27
Factors that determine the treatment for local and regional prostate cancer. Med Care (1996) 1.27
Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. Am J Physiol Cell Physiol (2000) 1.27
A prospective study of hepatic imaging in the detection of metastatic disease. Ann Surg (1982) 1.26
Conformational variability of a picornavirus capsid: pH-dependent structural changes of Mengo virus related to its host receptor attachment site and disassembly. Virology (1990) 1.26
Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J Virol (1998) 1.23
Respiratory exposures associated with silicon carbide production: estimation of cumulative exposures for an epidemiological study. Br J Ind Med (1984) 1.23
Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. J Biol Chem (1998) 1.22
Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol (1996) 1.21
Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-Delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells. J Immunol (2000) 1.21
Estimation of the diesel exhaust exposures of railroad workers: II. National and historical exposures. Am J Ind Med (1988) 1.21
Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun (2001) 1.20
Doses to organs and tissues from radon and its decay products. J Radiol Prot (2002) 1.20
Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection. Infect Immun (2006) 1.20
Structure determination of an Fab fragment that neutralizes human rhinovirus 14 and analysis of the Fab-virus complex. J Mol Biol (1994) 1.19